Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Oruka Therapeutics Inc (NASDAQ: ORKA) was $28.15 for the day, down -0.81% from the previous closing price of $28.38. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 0.63 million shares were traded. ORKA stock price reached its highest trading level at $30.09 during the session, while it also had its lowest trading level at $27.84.
Ratios:
Our analysis of ORKA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.94 and its Current Ratio is at 16.94. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on December 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $75.
On November 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $45.
On October 27, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $60.Guggenheim initiated its Buy rating on October 27, 2025, with a $60 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 14 ’25 when Venrock Healthcare Capital Par bought 88,794 shares for $11.44 per share. The transaction valued at 1,015,803 led to the insider holds 4,148,428 shares of the business.
Venrock Healthcare Capital Par bought 14,950 shares of ORKA for $173,868 on Feb 13 ’25. The 10% Owner now owns 4,059,634 shares after completing the transaction at $11.63 per share. On Feb 12 ’25, another insider, Venrock Healthcare Capital Par, who serves as the 10% Owner of the company, bought 8,971 shares for $11.86 each. As a result, the insider paid 106,396 and bolstered with 4,044,684 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORKA now has a Market Capitalization of 1362719872 and an Enterprise Value of 1018407872.
Stock Price History:
The Beta on a monthly basis for ORKA is -0.35, which has changed by 0.39734125 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, ORKA has reached a high of $32.28, while it has fallen to a 52-week low of $5.49. The 50-Day Moving Average of the stock is -0.35%, while the 200-Day Moving Average is calculated to be 68.86%.
Shares Statistics:
ORKA traded an average of 475.42K shares per day over the past three months and 422510 shares per day over the past ten days. A total of 48.38M shares are outstanding, with a floating share count of 42.67M. Insiders hold about 11.86% of the company’s shares, while institutions hold 85.36% stake in the company. Shares short for ORKA as of 1764288000 were 5497702 with a Short Ratio of 11.56, compared to 1761868800 on 5208430. Therefore, it implies a Short% of Shares Outstanding of 5497702 and a Short% of Float of 16.009999999999998.
Earnings Estimates
The performance of Oruka Therapeutics Inc (ORKA) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.55 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.52 and -$2.65 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$2.4, with 7.0 analysts recommending between -$2.03 and -$3.15.
